The Food and Drug administration on Monday announced Pfizer’s Covid-19 vaccine was cleared for emergency use on children ages 12-15.
Pfizer claims clinical trials showed “100% efficacy” in children, while “Side effects were similar to those experienced by adults,” reports Fox News.
“The most commonly reported side effects, which typically lasted several days, were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, and fever,” the FDA wrote at its website. “Of note, more people experienced these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose.”
Side effects among children encountered during the clinical trial, including one instance of a child with a 104°F fever, were documented on Twitter via journalist Alex Berenson:
Also: 35 teens had a fever of 102-103 after being vaccinated, and one a fever over 104.
Among those who received placebo 3 had fevers of 102-103, none over 104.
41 v 12 for “severe” fatigue,
25 v 2 for “severe” chills, etc
Nothing to see here, folks. Enjoy the shot! pic.twitter.com/WvL2NdQEwd
— Alex Berenson (@AlexBerenson) May 10, 2021
In a statement, acting FDA Commissioner Janet Woodcock attempted to tie the vaccine’s emergency use authorization to reopening efforts.
“Today’s action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic,” Woodcock stated.
“Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.”
Meanwhile, Pfizer is currently conducting clinical trials on healthy children aged 6-months to 11-years old, which started back in late March.
This content is courtesy of, and owned and copyrighted by, https://www.newswars.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.